Despite a drop in COVID product demand, Pfizer Inc (PFE) surpasses EPS expectations and advances key strategic initiatives.

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as ...

Investing.com -- Metsera Inc (NASDAQ:MTSR) stock rose 13% Tuesday as pharmaceutical giants Novo Nordisk (NYSE:NVO) and Pfizer ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported third-quarter profit of $3.54 billion. On a per-share basis, the New York-based company said it had net income of 62 cents.

Danish pharmaceutical powerhouse Novo Nordisk A/S ($NVO), renowned for its leadership in diabetes and obesity care, has ...

US stock market futures, Dow Jones, S&P 500 and Nasdaq today saw a decline as tech stocks led a pullback after Mondays ...